Supplemental Table 3. CBPI and Lameness scores of the individual dogs during the study

| Treatment Group | Patient ID Number | Lameness Score | Pain Severity Reduction | Pain Interference Reduction | Limb Discomfort Post Injection (Y/N) |
|-----------------|-------------------|----------------|-------------------------|-----------------------------|-------------------------------------|
|                 |                   | Day 0 | Day 30 | Day 90 | Day 0 | Day 30 | Day 90 | Day 0 | Day 30 | Day 90 |                     |
| Placebo         | P-1               | 2     | 1     | 0     | 4     | 2     | 1.5    | 5     | 1.33  | 1.33  | Y**                 |
| Placebo         | P-2               | 1     | 0     | 2     | 0.5   | 0.25  | 0.25   | 1     | 0.17  | 0.17  | N                    |
| Placebo         | P-3               | 1     | 5     | 3     | 5     | 5     | 4.75   | 8.83  | 7.83  | 8.83  | N                    |
| Placebo         | P-4               | 5     | 5     | 4     | 5.8   | 6.1   | 6.2    | 6     | 6.17  | 6.17  | N                    |
| 5M              | 5-1               | 1     | 1     | 1     | 3     | 2.5   | 1.5    | 3.33  | 3.33  | 2.5   | Y**                 |
| 5M              | 5-2               | 2     | 1     | 0     | 4.25  | 4.75  | 4.7    | 5     | 4.5   | 4.67  | N                    |
| 5M              | 5-3               | 8     | 5     | 6     | 8     | 5     | 5.8    | 8.5   | 5     | 6.17  | N                    |
| 5M              | 5-4               | 8     | 5     | 5     | 7.6   | 5.7   | 5.3    | 8     | 5.67  | 5.5   | N                    |
| 5M              | 5-5               | 5     | 3     | 3     | 4     | 2.3   | 2.3    | 3.67  | 2     | 2     | N                    |
| 25M             | 25-1              | 1     | 3     | NA    | 4     | 5     | NA     | 9.17  | 5.3   | NA    | Y**                 |
| 25M             | 25-2              | 1     | 0     | 1     | 0.25  | 0.75  | 1      | 1.17  | 0.83  | 0.83  | N                    |
| 25M             | 25-3              | 2     | 1     | 0     | 3     | 0.75  | 1.5    | 5.17  | 1.67  | 2.5   | N                    |
| 25M             | 25-4              | 5     | 2     | 1     | 2.5   | 1.5   | 1.3    | 3.83  | 2.5   | 1.5   | N                    |
| 25M             | 25-5              | 8     | 8     | 6     | 7     | 7.5   | 5.6    | 5.5   | 5.5   | 5.17  | Y**                 |
| 25M             | 25-6              | 7     | 7     | 7     | 5.4   | 5.4   | 5.4    | 4.83  | 4.83  | 4.83  | N                    |
| 50M             | 50-1              | 2     | 0     | 0     | 0.75  | 0.25  | 0.25   | 1.33  | 0.33  | 0.33  | N                    |
| 50M             | 50-2              | 1     | 0     | 0     | 3.25  | 3     | 2.2    | 7     | 4.5   | 2.17  | N                    |
| 50M             | 50-3              | 4     | 0     | 0     | 2.5   | 0.4   | 0      | 3.17  | 0.67  | 0     | N                    |
| 50M             | 50-4*             | 7     | 6     | 5     | 5.4   | 7.6   | 5.8    | 4.83  | 8     | 5.67  | Y**                 |
| 50M             | 50-5*             | 6     | 6     | 6     | 6.6   | 7.2   | 6.3    | 6.67  | 7.17  | 6     | N                    |

*: Two dogs were excluded from the study because they received other medications or treatments throughout the study that were not permitted in the inclusion criteria

**: Dogs with limb discomfort post injection

NA: Data was not collected

5M: 5 x 10⁶ cells
25M: 25 x 10⁶ cells
50M: 50 x 10⁶ cells